open access

Ahead of Print
Research paper
Published online: 2021-11-22
Get Citation

Analysis of incidence and overall survival of patients with vulvar cancer in Poland in 2008–2016 — implications for cancer registries

Waldemar Wierzba12, Mateusz Jankowski3, Krzysztof Placiszewski2, Piotr Ciompa1, Artur J. Jakimiuk45, Anna Danska-Bidzinska6
DOI: 10.5603/GP.a2021.0154
Affiliations
  1. University of Humanities and Economics in Lodz, Poland
  2. Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
  3. School of Public Health, Centre of Postgraduate Medical Education, Warsaw, Poland
  4. Department of Obstetrics and Gynecology, Central Clinical Hospital of Interior Affairs and Administration, Warsaw, Poland
  5. Center of Reproductive Health, Institute of Mother and Child, Warsaw, Poland
  6. Chair and Department of Obstetrics, Gynaecology and Oncology, 2nd Faculty of Medicine, Medical University of Warsaw, Poland

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2021-11-22

Abstract

Objectives: To analyze the incidence and overall survival rate of patients with vulvar cancer in Poland, based on the reporting data from the National Health Fund.

Material and methods: The incidence of vulvar cancer in Poland in 2008–2016 (9-year follow-up period) by voivodship and the number of patients undergoing combined hospital treatment were analyzed. For the group of patients treated systemically, overall survival (OS) probability was calculated using the Kaplan-Meier estimation method.

Results: In the period 2008–2016 in Poland, the diagnosis of malignant neoplasm of the vulva (C51% group) was made in 29,702 patients. The mean annual prevalence rate per 100,000 inhabitants was 8.3 ± 1.2 for Poland. The largest numbers of patients were reported in Mazowieckie and Slaskie voivodeships and the lowest in Opolskie and Podlaskie voivodeships. The median overall survival of patients treated with the combined method in 2008–2016 in Poland was 64.7 months (95% Cl: 58.0–70.0). One-year survival rate was observed in 77.6% of patients, 2-year in 64.4%, 3-year in 58%, over 5 years — 54.22%.

Conclusions: In the years 2008–2016 in Poland, based on the data reported to the National Health Fund, the incidence of vulvar cancer was 4 times higher than the statistics of the National Cancer Registry, the WHO or the USA, which indicates either substantive or reporting errors. In Poland, 54% of patients treated with the combined therapy survive over 5 years which is a much lower result compared to highly developed countries.

Abstract

Objectives: To analyze the incidence and overall survival rate of patients with vulvar cancer in Poland, based on the reporting data from the National Health Fund.

Material and methods: The incidence of vulvar cancer in Poland in 2008–2016 (9-year follow-up period) by voivodship and the number of patients undergoing combined hospital treatment were analyzed. For the group of patients treated systemically, overall survival (OS) probability was calculated using the Kaplan-Meier estimation method.

Results: In the period 2008–2016 in Poland, the diagnosis of malignant neoplasm of the vulva (C51% group) was made in 29,702 patients. The mean annual prevalence rate per 100,000 inhabitants was 8.3 ± 1.2 for Poland. The largest numbers of patients were reported in Mazowieckie and Slaskie voivodeships and the lowest in Opolskie and Podlaskie voivodeships. The median overall survival of patients treated with the combined method in 2008–2016 in Poland was 64.7 months (95% Cl: 58.0–70.0). One-year survival rate was observed in 77.6% of patients, 2-year in 64.4%, 3-year in 58%, over 5 years — 54.22%.

Conclusions: In the years 2008–2016 in Poland, based on the data reported to the National Health Fund, the incidence of vulvar cancer was 4 times higher than the statistics of the National Cancer Registry, the WHO or the USA, which indicates either substantive or reporting errors. In Poland, 54% of patients treated with the combined therapy survive over 5 years which is a much lower result compared to highly developed countries.

Get Citation

Keywords

vulvar cancer; overall survival; combined therapy; retrospective analysis; Poland

About this article
Title

Analysis of incidence and overall survival of patients with vulvar cancer in Poland in 2008–2016 — implications for cancer registries

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2021-11-22

DOI

10.5603/GP.a2021.0154

Keywords

vulvar cancer
overall survival
combined therapy
retrospective analysis
Poland

Authors

Waldemar Wierzba
Mateusz Jankowski
Krzysztof Placiszewski
Piotr Ciompa
Artur J. Jakimiuk
Anna Danska-Bidzinska

References (15)
  1. Kornafel J, Mądry R, Bidziński M. Rak sromu. In: Kornafel J, Mądry R. ed. Nowotwory kobiecego układu płciowego. Wytyczne Polskiego Towarzystwa Onkologii Klinicznej, , Warszawa 2013.
  2. Minar L, Felsinger M, Cihalova M, et al. Vulvar cancer recurrence - an analysis of prognostic factors in tumour-free pathological margins patients group. Ginekol Pol. 2018; 89(8): 424–431.
  3. Sznurkowski JJ, Milczek T, Emerich J. Prognostic factors and a value of 2009 FIGO staging system in vulvar cancer. Arch Gynecol Obstet. 2013; 287(6): 1211–1218.
  4. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. ttp://onkologia.org.pl/nowotwory-sromu-pochwy-kobiet (2021.05.01).
  5. World Health Organization. International Statistical Classification of Diseases and Related Health Problems(ICD-10). http://stat.gov.pl/Klasyfikacje/doc/icd10/pdf/ICD10TomI.pdf (2021.05.01).
  6. Government of Poland. PESEL. https://obywatel.gov.pl/pl/dokumenty-i-dane-osobowe/czym-jest-numer-pesel (2021.05.01).
  7. Journal of Laws. Ustawa z dnia 27.08.2008 roku o Świadczeniach Opieki Zdrowotnej finansowanych ze środków publicznych (Dz. U. 2008. nr 164 poz. 1027 z późn. zm). http://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20042102135 (2021.05.01).
  8. Fendler W, Chałubińska J, Młynarski W. ethods of survival analysis applied in oncology - assumptions, methods and common pitfalls. Onkol Prak Klin. 2011; 7(2): 89–101.
  9. National Cancer Institute (US). Cancer Stat Facts: Vulvar Cancer. https://seer.cancer.gov/statfacts/html/vulva.html (2021.05.01).
  10. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1): 7–30.
  11. Woelber L, Trillsch F, Kock L, et al. Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol. 2013; 5(3): 183–192.
  12. Barlow EL, Kang YJ, Hacker NF, et al. Changing trends in vulvar cancer incidence and mortality rates in Australia since 1982. Int J Gynecol Cancer. 2015; 25(9): 1683–1689.
  13. Banas T, Pitynski K, Jach R, et al. Primary vulvo-vaginal cancers: trends in incidence and mortality in Poland (1999-2012). Gynecol Obstet Invest. 2015; 80(4): 240–245.
  14. Perzyło K, Miotła P, Lis E, et al. [Therapeutic and prognostic value of lymphadenectomy in gynecological oncology]. Ginekol Pol. 2013; 84(7): 630–636.
  15. Gaudineau A, Weitbruch D, Quetin P, et al. Neoadjuvant chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the vulva. Oncol Lett. 2012; 4(4): 719–722.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl